Search

Background: Monocyte chemoattractant protein-1 (MCP-1) participates in the recruitment of mononuclear cells to the vessel wall. Hypothesis: The aim of the study was to evaluate the potential association between serum concentration of MCP-1 and risk of future cardiovascular events in patients with chronic coronary heart disease. Methods: A nested case control design was used. Baseline serum samples were taken from patients with coronary heart disease who were enrolled in a secondary prevention study. The MCP-1 levels were measured in those patients who had recurrent cardiovascular events during follow-up (n=23 3) and compared with levels in age- and gender-matched controls. Results: There were no differences in serum MCP-1 levels between cases and controls. The relative odds of a recurrent cardiovascular event for each 1 standard deviation difference in MCP-1 serum concentration (160 pg/ml) was 1.19 (95% confidence interval, 0.95–1.45). No increase in the relative odds for recurrent cardiovascular events was observed per increasing tertiles of MCP-1 concentrations. Conclusion: Elevated MCP-1 levels are not associated with long-term risk of cardiovascular events in patients with stable coronary disease.

Summary Background:The two most useful methods for myocardial viability assessment are perfusion imaging and dobutamine echocardiography. Hypothesis:The present study investigated the additive value of a new method, dobutamine technetium 99m ( 99m Tc)-sestamibi-gated single-photon emission computed tomography (SPECT), which combines these two modalities, to the prediction of wall motion improvement after revascularization. Methods: Fifty-five consecutive patients with ischemic cardiomyopathy, who were referred for viability evaluation, underwent resting and dobutamine (dose, 5‐10 µkg/kg/min) gated SPECT with 99m Tc-sestamibi. Of these patients, 36 underwent coronary artery bypass graft (CABG) within 1 month of the study and 32 had repeat resting gated SPECT within 1 year. Global and regional wall motion, wall thickness, and perfusion were simultaneously analyzed at rest and after dobutamine using the 20-segment model; the sestamibi uptake and wall motion response to dobutamine of each segment were rated quantitatively. Based on these findings, the segments were categorized as normal, viable, or nonviable. The predictive values for wall motion improvement were assessed by perfusion, using cutoffs of 50 and 60% of sestamibi uptake, and thereafter by the addition of dobutamine response in the segments that were rated nonviable. Results: Of the 1,080 myocardial segments studied, 906 (84%) had abnormal wall motion and were analyzed for viability. Concordance between perfusion and wall motion response to dobutamine was 60% with the 50% cutoff of sestamibi uptake, and increased to 65% with the 60% sestamibi cutoff (p < 0.04). The respective predictive values of wall motion improvement using the 50 and 60% cutoff points were as follows: sensitivity 93 and 70%, respectively, (p < 0.01); specificity 59 and 86% (p < 0.001), respectively; accuracy 77% for both. The addition of the wall motion response to dobutamine to the assessment of the nonviable segments by perfusion (60% cutoff) increased the sensitivity from 70 to 85% (p = 0.001) and the negative predictive value from 70 to 81% (p = 0.009); the positive predictive value remained high (86 vs. 82%). No additive value of wall motion response to dobutamine was demonstrated for nonviable segments by perfusion with a 50% cutoff. Conclusion:Dobutamine sestamibi-gated SPECT is a feasible method for the analysis of myocardial perfusion, function, and contractile reserve of individual myocardial segments in patients with ischemic cardiomyopathy. Viability assessment based on a threshold of 60% uptake of sestamibi, with the addition of the wall motion response to dobutamine in the nonviable segments, seems to yield better predictive values for wall motion improvement after CABG.

Background More and more young people are being referred for evaluation or screening for coronary artery disease (CAD). However, the value of myocardial perfusion imaging (MPI) in this population is unclear, especially in the absence of symptoms. Methods The study sample included 1765 consecutive patients less than 51 years old who were referred to a major medical center for stress/rest MPI study. Clinical and MPI variables were compared between patients with and without known CAD, by gender. Results There were 1346 (76%) men and 419 (24%) women of mean age 44 ± 6 years; 461 (26%) had known CAD. Stress-induced ischemia was detected in 321 patients (18.2%) and significant ischemia in 131 (7.4%); there was no difference in the rate or severity of ischemia by presence of symptoms. Among those without known CAD, the rate of stress-induced ischemia by MPI was significantly lower in women than men. On logistic regression analysis, the independent predictors of ischemia in men were high cholesterol, diabetes, angina during stress testing, ST depression, and smoking (P

Background: Elevated levels of inflammatory biomarkers and brain natriuretic peptide (BNP) are associated with increased mortality in patients with heart failure (HF). Hypothesis: The aim of the current study was to assess the correlation between circulating biomarkers and ventricular tachyarrhythmias among patients with HF. Methods: Blood samples from 50 stable ambulatory HF patients with moderate to severe systolic left ventricular (LV) dysfunction and an implantable cardioverter defibrillator (ICD) were analyzed for interleukin 6 (IL-6), tumor necrosis factor-alpha (TNF-α), high-sensitivity C-reactive protein (hsCRP) and BNP. Thereafter, the patients were followed for a mean period of 152 ± 44 days, during which ventricular tachyarrhythmias were recorded by the ICDs. Results: Follow-up data were obtained from 47 patients. Of them, 45 (96%) had ischemic cardiomyopathy, 38 (81%) had New York Heart Association class I–II, 43 (91%) were males, and the mean age was 68.6 ± 11.1 years. During follow-up, 5 patients (11%) had nonsustained ventricular tachycardia (NSVT), 6 patients (13%) had sustained ventricular tachycardia (VT) or ventricular fibrillation (VF) and 36 patients (76%) had no events. The circulating biomarkers' levels upon enrollment were not significantly different between patients who subsequently had NSVT or VT/VF and patients who were free of events. Conclusions: No correlation was found between plasma levels of IL-6, TNF-α, hsCRP and BNP and ventricular arrhythmic events among stable HF patients during an intermediate term follow-up of 5.1 months. Further studies are still required to assess the association between these biomarkers and long-term risk of ventricular tachyarrhythmia. Copyright © 2007 Wiley Periodicals, Inc.

Background: Monocyte chemoattractant protein‐1 (MCP‐1) participates in the recruitment of mononuclear cells to the vessel wall. Hypothesis: The aim of the study was to evaluate the potential association between serum concentration of MCP‐1 and risk of future cardiovascular events in patients with chronic coronary heart disease. Methods: A nested case control design was used. Baseline serum samples were taken from patients with coronary heart disease who were enrolled in a secondary prevention study. The MCP‐1 levels were measured in those patients who had recurrent cardiovascular events during follow‐up (n=23 3) and compared with levels in age‐ and gender‐matched controls. Results: There were no differences in serum MCP‐1 levels between cases and controls. The relative odds of a recurrent cardiovascular event for each 1 standard deviation difference in MCP‐1 serum concentration (160 pg/ml) was 1.19 (95% confidence interval, 0.95–1.45). No increase in the relative odds for recurrent cardiovascular events was observed per increasing tertiles of MCP‐1 concentrations. Conclusion: Elevated MCP‐1 levels are not associated with long‐term risk of cardiovascular events in patients with stable coronary disease.

Background: The interruption of oral anticoagulant (OAC) administration is sometimes indicated in patients with mechanical heart valves, mainly before noncardiac surgery, non-surgical interventions, and pregnancy. Unfractionated heparin (UH) is currently the substitute for selected patients. Low-molecular-weight heparin (LMWH) offers theoretical advantages over UH, but is not currently considered in clinical guidelines as an alternative to UH in patients with prosthetic valves. Hypothesis: The aim of the present study was to review the data accumulated so far on the use of LMWH in this patient population and to discuss its applicability in common practice. Methods: For this paper, the current medical literature on LMWH in patients with mechanical heart valves was extensively reviewed. Results: There were eight series and six case reports. None of the studies was randomized, and only one was prospective. Data to establish the thromboembolic risk were incomplete. After excluding case reports, the following groups were constructed: (a) short-term administration, after valve insertion (n = 212);(b) short-term, perioperative (noncardiac)/periprocedural (n = 114);(c) long-term, due to intolerance to OAC (n = 16);(d) long-term, in pregnancy (n = 10). The incidence rate of thromboembolism was 0.9% for all the studies and 0.5, 0, 20, and 0% in groups a, b, c, and d, respectively; for hemorrhage, the overall rate was 3.4% (3.8, 2.6, 10, and 0% for the respective groups). Conclusions: In patients with mechanical heart valves, short-term LMWH therapy compares favorably with UH. Data on mid- and long-term LMWH administration in these patients are sparse. Further randomized studies are needed to confirm the safety and precise indications for the use of LMWH in patients with mechanical heart valves.

The short-term hemodynamic and possible arrhythmogenic effects of intravenous salbutamol at a dose of 30 or 60 micrograms/min were evaluated in 14 patients with severe chronic left ventricular dysfunction using equilibrium radionuclide angiocardiography and electrocardiographic monitoring. Salbutamol infusions at a dose of 30 micrograms/min did not cause significant hemodynamic changes; however, at a dose of 60 micrograms/min there was a significant increase in stroke volume, cardiac output, and left ventricular ejection fraction. Heart rate increased significantly while systemic peripheral resistance decreased significantly. Two patients developed ventricular premature beats and another two supraventricular tachycardia, but none were associated with adverse consequences. Thus, high-dose intravenous salbutamol is effective and safe, and may be used in the acute management of patients with poor left ventricular function.

To test the value of combining treadmill exercise with radionuclide angiography for detecting exercise-induced left ventricular dysfunction, ejection fractions were calculated at rest, peak supine bicycle exercise, and during three supine post-treadmill recovery periods (2-4 min, recovery 1;4-6 min, recovery 2;8-10 min, recovery 3) in ten coronary artery disease patients and eight normal subjects. Both the normal subjects and coronary artery disease patients had normal resting ejection fractions (greater than 0.50). In the normal subjects the mean ejection fraction increased significantly (p less than 0.005) from rest (0.61 +/- 0.03) to peak supine bicycle exercise (0.71 +/- 0.04), and the mean ejection fraction also remained significantly higher (p less than 0.005) at rest than during 10 min post-treadmill exercise. However, the coronary artery disease patients did not significantly change the mean ejection fractions from rest (0.59 +/- 0.06) to peak supine bicycle exercise (0.55 +/- 0.08), and the average ejection fraction during each one of the post-treadmill recovery periods was not significantly different from rest. At the third recovery period all the normals but no coronary artery disease patients had higher ejection fraction than the resting ejection fraction. We thus conclude that the magnitude of change in ejection fraction from rest to 8-10 min post-treadmill exercise in patients with normal resting ejection fraction may be helpful in identifying those with coronary disease.

The rest and exercise ECG, /sup 201/thallium myocardial scintigram (/sup 201/T1), and radionuclide ventriculography are noninvasive procedures which can be used to evaluate myocardial damage and ischemia. To compare these procedures and to obtain baseline information, 85 male patients with coronary heart disease were evaluated prior to beginning an exercise program. Findings at rest included Q waves or bundle branch block in 54%; 47% had /sup 201/T1 redistribution defects and 33% an abnormal ejection fraction (EF). Of the 39 patients with normal ECGs, 31 had no /sup 201/T1 defects and only of these 31 (3%) had an abnormal EF. Abnormal EF or /sup 201/T1 redistribution defects did not occur in patients without a history of myocardial infarction. Abnormal resting EF occurred in 63% of patients with abnormal versus 7% of those with normal /sup 201/T1 redistribution scans. Exercise test results included an abnormal ST-segment response in 80%, an abnormal EF response in 65%, and a /sup 201/T1 ischemic defect in 37%. Twenty patients had exercise-induced ST elevation, and this phenomenon was more related to ventricular aneurysms than to ischemia. /sup 201/Thallium imaging, radionuclide ventriculography, and the ECG provide results regarding myocardial damage that agree by more than chance, while themore » exercise induced ST-segment changes did not agree with the radionuclide indications of exercise-induced ischemia.« less

We have studied the changes induced in atherosclerotic arteries by a CO2 laser beam delivered through a silver halide optical fiber. We found that the crater depth and diameter correlate with the total energy delivered and with the mode of delivery. Short-duration high-power pulses caused shallower and narrower craters and less damage to the arterial wall compared to the same energy delivered as low-power pulses of long duration. Thus, high-power pulses for short periods may be an effective and safe procedure for evaporization of atherosclerotic plaques.

The effect of metoprolol on global left ventricular function during exercise was analyzed with nuclear ventriculography in 17 patients with ischemic heart disease. All had stable angina pectoris and ST-segment depression of more than 0.1 mV during treadmill exercise when not taking metoprolol. Each patient was stressed with supine bicycle exercise to the same load on a maintenance dose of metoprolol (100 mg X 2/day) and on a second occasion without the drug, the two being separated by 7 days. The mean heart rate and systolic blood pressure were significantly reduced both at rest and exercise with metoprolol. There was no significant difference of rest left ventricular ejection fraction with or without metoprolol. At exercise, however, every patient showed improvement of left ventricular function, the average left ventricular ejection fraction increasing by 14% (+/- 6) relative to the same exercise without metoprolol (p less than 0.001). We conclude that chronic metoprolol treatment in patients with ischemic heart disease can ameliorate left ventricular dysfunction induced by exercise and may thereby reduce myocardial ischemia.